Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

News Releases

19 Jan '2023
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J. , Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes
19 Oct '2022
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated   in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62 .5% and   37 .5